Campbell & Co Investment Adviser’s Krystal Biotech KRYS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,795	Closed	-$4.6M	–	1208
2026 Q1	$4.6M	Buy	+17,795	New	+$4.74M	0.26%	83
2025 Q4	–	Sell	-1,721	Closed	-$304K	–	1274
2025 Q3	$304K	Sell	1,721 -270	-14%	-$40.4K	0.02%	910
2025 Q2	$274K	Buy	+1,991	New	+$292K	0.02%	983
2024 Q2	–	Sell	-2,479	Closed	-$441K	–	1202
2024 Q1	$441K	Buy	+2,479	New	+$344K	0.04%	753

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Campbell & Co Investment Adviser's KRYS Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 17,795 shares — an estimated $4.6M sold.

Campbell & Co Investment Adviser first reported a position in KRYS in Q1 2024 and held it in 4 quarters. The position peaked at $4.6M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 17,795 Krystal Biotech shares in Q2 2026, an estimated $4.6M.
Campbell & Co Investment Adviser first reported a position in Krystal Biotech in Q1 2024 and held it in 4 quarters.
Campbell & Co Investment Adviser's Krystal Biotech position peaked at $4.6M in Q1 2026.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.